Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 9 (September)

1. Characteristics of DEAE-dextran-MMA graft copolymer as a nonviral gene carrier.
   Nanomedicine, 3(3): 184-91. [Abstract] [Full-text]
2. Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults.
   Am J Ophthalmol, 144(3): 469-70. [Abstract] [Full-text]
3. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.
   Nanomedicine, 3(3): 173-83. [Abstract] [Full-text]
4. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
   Nanomedicine, 3(3): 239-43. [Abstract] [Full-text]
5. Photodynamic therapy with verteporfin for corneal neovascularization.
   Am J Ophthalmol, 144(3): 390-395. [Abstract] [Full-text]
6. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides.
   FASEB J, 21(11): 2664-71. [Abstract] [Full-text]
7. Development of a miniaturised drug delivery system with wireless power transfer and communication.
   IET Nanobiotechnol, 1(5): 80-6. [Abstract] [Full-text]
8. An examination of the rheological and mucoadhesive properties of poly(acrylic acid) organogels designed as platforms for local drug delivery to the oral cavity.
   J Pharm Sci, 96(10): 2632-46. [Abstract] [Full-text]
9. Effect of polymer molecular weight on the production of drug nanoparticles.
   J Pharm Sci, 96(10): 2655-66. [Abstract] [Full-text]
10. Role of nanotechnology in pharmaceutical product development.
    J Pharm Sci, 96(10): 2547-65. [Abstract] [Full-text]
11. Effects of cyclodextrins on drug delivery through biological membranes.
    J Pharm Sci, 96(10): 2532-46. [Abstract] [Full-text]
12. Thrombolytic therapy for acute ischemic stroke.
    J Neurol Sci, 261(1): 55-62. [Abstract] [Full-text]
13. The use of intraventricular thrombolytics in intraventricular hemorrhage.
    J Neurol Sci, 261(1): 84-8. [Abstract] [Full-text]
14. ICH aspiration and thrombolysis.
    J Neurol Sci, 261(1): 80-3. [Abstract] [Full-text]
15. Development of a slow non-viral DNA release system from PDLLA scaffolds fabricated using a supercritical CO2 technique.
    Biotechnol Bioeng, 98(3): 679-93. [Abstract] [Full-text]
16. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
    Clin Cancer Res, 13(17): 5150-5. [Abstract] [Full-text]
17. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
    PLoS Pathog, 3(8): e122. [Abstract] [Full-text]
18. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    J Natl Cancer Inst, 99(17): 1335-9. [Abstract] [Full-text]
19. Radical surgery and IVA-chemotherapeutic regimen to treat embryonal rhabdomyosarcoma of the urachus: case report.
    Pediatr Hematol Oncol, 24(7): 543-50. [Abstract] [Full-text]
20. Hodgkin lymphoma in a child with sickle cell anemia.
    Pediatr Hematol Oncol, 24(7): 531-5. [Abstract] [Full-text]
21. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
    Cancer Lett, 256(1): 25-8. [Abstract] [Full-text]
22. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Clin Infect Dis, 45(7): 925-32. [Abstract] [Full-text]
23. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.
    Clin Infect Dis, 45(7): 918-24. [Abstract] [Full-text]
24. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis.
    Clin Infect Dis, 45(7): 908-15. [Abstract] [Full-text]
25. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
    J Thorac Oncol, 2(9): 845-53. [Abstract] [Full-text]
26. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
    J Thorac Oncol, 2(9): 838-44. [Abstract] [Full-text]
27. Photodynamic therapy for the treatment of actinic cheilitis.
    Photodermatol Photoimmunol Photomed, 23(5): 209-10. [Abstract] [Full-text]
28. Efficacy of ALA-PDT vs blue light in the treatment of acne.
    Photodermatol Photoimmunol Photomed, 23(5): 186-90. [Abstract] [Full-text]
29. Effects of an integrated clinical information system on medication safety in a multi-hospital setting.
    Am J Health Syst Pharm, 64(18): 1969-77. [Abstract] [Full-text]
30. Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients.
    Am J Health Syst Pharm, 64(18): 1935-42. [Abstract] [Full-text]
31. End-of-procedure cefazolin concentrations after administration for prevention of surgical-site infection.
    Am J Health Syst Pharm, 64(18): 1927-34. [Abstract] [Full-text]
32. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration.
    Ophthalmology, 114(9): 1713-21. [Abstract] [Full-text]
33. Electroporation-mediated gene transfer of the Na+,K+ -ATPase rescues endotoxin-induced lung injury.
    Am J Respir Crit Care Med, 176(6): 582-90. [Abstract] [Full-text]
34. Growth hormone replacement throughout life: insights into age-related responses to treatment.
    Growth Horm IGF Res, 17(5): 369-82. [Abstract] [Full-text]
35. In situ-forming hydrogels for sustained ophthalmic drug delivery.
    J Control Release, 122(2): 119-34. [Abstract] [Full-text]
36. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles.
    J Control Release, 122(2): 141-50. [Abstract] [Full-text]
37. Quantitative structure-permeation relationship for iontophoretic transport across the skin.
    J Control Release, 122(2): 165-72. [Abstract] [Full-text]
38. Analysis and modeling of swelling and erosion behavior for pure HPMC tablet.
    J Control Release, 122(2): 181-8. [Abstract] [Full-text]
39. Polymer mobilization and drug release during tablet swelling. A 1H NMR and NMR microimaging study.
    J Control Release, 122(2): 199-205. [Abstract] [Full-text]
40. Development of bionanocapsules targeting brain tumors.
    J Control Release, 122(2): 159-64. [Abstract] [Full-text]
41. Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl.
    J Control Release, 122(2): 135-40. [Abstract] [Full-text]
42. Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum.
    BMC Cancer, 7: 155. [Abstract] [Full-text]
43. Low temperature direct 3D printed bioceramics and biocomposites as drug release matrices.
    J Control Release, 122(2): 173-80. [Abstract] [Full-text]
44. Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells.
    J Control Release, 122(2): 151-8. [Abstract] [Full-text]
45. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer.
    J Clin Oncol, 25(26): 4146-52. [Abstract] [Full-text]
46. Limited-stage small-cell lung cancer: the current status of combined-modality therapy.
    J Clin Oncol, 25(26): 4137-45. [Abstract] [Full-text]
47. Chemoradiotherapy in malignant glioma: standard of care and future directions.
    J Clin Oncol, 25(26): 4127-36. [Abstract] [Full-text]
48. Chemoradiation in the management of esophageal cancer.
    J Clin Oncol, 25(26): 4110-7. [Abstract] [Full-text]
49. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Cancer, 110(6): 1178-86. [Abstract] [Full-text]
50. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Cancer, 110(6): 1235-40. [Abstract] [Full-text]
51. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
    Cancer, 110(6): 1195-200. [Abstract] [Full-text]
52. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
    Cancer, 110(6): 1307-12. [Abstract] [Full-text]
53. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cancer, 110(6): 1295-302. [Abstract] [Full-text]
54. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
    Cancer, 110(6): 1329-37. [Abstract] [Full-text]
55. Liberal or restrictive fluid administration in fast-track colonic surgery: a randomized, double-blind study.
    Br J Anaesth, 99(4): 500-8. [Abstract] [Full-text]
56. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum.
    Int J Antimicrob Agents, 30(4): 325-9. [Abstract] [Full-text]
57. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
    Cancer Chemother Pharmacol, 60(6): 907-14. [Abstract] [Full-text]
58. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
    Cancer Chemother Pharmacol, 60(6): 871-82. [Abstract] [Full-text]
59. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
    Cancer Chemother Pharmacol, 60(6): 863-9. [Abstract] [Full-text]
60. Medication therapy management: its relationship to patient counseling, disease management, and pharmaceutical care.
    J Am Pharm Assoc (2003), 47(5): 620-8. [Abstract] [Full-text]
61. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
    Br J Cancer, 97(6): 712-6. [Abstract] [Full-text]
62. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.
    Br J Cancer, 97(6): 735-40. [Abstract] [Full-text]
63. Translation of pharmacogenetics into clinically relevant testing modalities.
    Clin Pharmacol Ther, 82(4): 373-6. [Abstract] [Full-text]
64. An assessment of direct-to-consumer advertising of prescription drugs.
    Clin Pharmacol Ther, 82(4): 357-60. [Abstract] [Full-text]
65. The emerging role of pharmacogenomics in biologics.
    Clin Pharmacol Ther, 82(4): 466-71. [Abstract] [Full-text]
66. Finding a liability-free space in which personalized medicine can bloom.
    Clin Pharmacol Ther, 82(4): 461-5. [Abstract] [Full-text]
67. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
    Clin Pharmacol Ther, 82(4): 402-9. [Abstract] [Full-text]
68. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
    Scand J Immunol, 66(4): 465-75. [Abstract] [Full-text]
69. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.
    Br J Haematol, 139(1): 90-3. [Abstract] [Full-text]
70. Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease.
    Clin Immunol, 125(1): 60-6. [Abstract] [Full-text]
71. Inappropriate prescribing in an older ED population.
    Am J Emerg Med, 25(7): 804-7. [Abstract] [Full-text]
72. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response.
    Acta Biomater, 3(6): 838-50. [Abstract] [Full-text]
73. Diffuse-interface theory for structure formation and release behavior in controlled drug release systems.
    Acta Biomater, 3(6): 851-64. [Abstract] [Full-text]
74. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
    Am J Clin Pathol, 128(4): 630-7. [Abstract] [Full-text]
75. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
    J Clin Oncol, 25(27): 4270-7. [Abstract] [Full-text]
76. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.
    J Clin Oncol, 25(27): 4201-9. [Abstract] [Full-text]
77. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    J Clin Oncol, 25(27): 4217-23. [Abstract] [Full-text]
78. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
    J Clin Oncol, 25(27): 4224-30. [Abstract] [Full-text]
79. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Leukemia, 21(10): 2109-16. [Abstract] [Full-text]
80. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.
    Leukemia, 21(10): 2117-27. [Abstract] [Full-text]
81. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Bone Marrow Transplant, 40(7): 651-8. [Abstract] [Full-text]
82. PDGF-BB released in tendon repair using a novel delivery system promotes cell proliferation and collagen remodeling.
    J Orthop Res, 25(10): 1358-68. [Abstract] [Full-text]
83. Locally delivered lovastatin nanoparticles enhance fracture healing in rats.
    J Orthop Res, 25(10): 1351-7. [Abstract] [Full-text]
84. Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.
    J Med Virol, 79(11): 1640-9. [Abstract] [Full-text]
85. Temozolomide in pediatric low-grade glioma.
    Pediatr Blood Cancer, 49(6): 808-11. [Abstract] [Full-text]
86. Infections with viridans group streptococci in children with cancer.
    Pediatr Blood Cancer, 49(6): 774-80. [Abstract] [Full-text]
87. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
    Pediatr Blood Cancer, 49(6): 803-7. [Abstract] [Full-text]
88. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen.
    Pediatr Blood Cancer, 49(6): 852-4. [Abstract] [Full-text]
89. Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor.
    Pediatr Blood Cancer, 49(6): 864-6. [Abstract] [Full-text]
90. Adverse effects of highly active antiretroviral therapy in developing countries.
    Clin Infect Dis, 45(8): 1093-101. [Abstract] [Full-text]
91. Ten-year predicted coronary heart disease risk in HIV-infected men and women.
    Clin Infect Dis, 45(8): 1074-81. [Abstract] [Full-text]
92. Medication errors among acutely ill and injured children treated in rural emergency departments.
    Ann Emerg Med, 50(4): 361-7, 367.e1-2. [Abstract] [Full-text]
93. Pathologically activated therapeutics for neuroprotection.
    Nat Rev Neurosci, 8(10): 803-8. [Abstract] [Full-text]
94. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
    Blood, 110(7): 2316-23. [Abstract] [Full-text]
95. Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome.
    AJR Am J Roentgenol, 189(4): 956-65. [Abstract] [Full-text]
96. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome.
    J Am Acad Child Adolesc Psychiatry, 46(10): 1349-56. [Abstract] [Full-text]
97. Effectiveness of antibiotic prophylaxis in third molar surgery: a meta-analysis of randomized controlled clinical trials.
    J Oral Maxillofac Surg, 65(10): 1909-21. [Abstract] [Full-text]
98. Prognostic evaluation by clinical exercise test scores in patients treated with primary percutaneous coronary intervention or fibrinolysis for acute myocardial infarction (a Danish Trial in Acute Myocardial Infarction-2 Sub-Study).
    Am J Cardiol, 100(7): 1074-80. [Abstract] [Full-text]
99. Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF/poly(DL-lactic-co-glycolic acid) implants.
    J Control Release, 122(3): 331-7. [Abstract] [Full-text]
100. Electrophoretic purification of tumor-targeted polyethylenimine-based polyplexes reduces toxic side effects in vivo.
     J Control Release, 122(3): 236-45. [Abstract] [Full-text]
101. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents.
     J Control Release, 122(3): 324-30. [Abstract] [Full-text]
102. Polymer platforms for drug delivery and biomedical imaging.
     J Control Release, 122(3): 269-77. [Abstract] [Full-text]
103. Multifunctional envelope-type nano device for non-viral gene delivery: concept and application of Programmed Packaging.
     J Control Release, 122(3): 246-51. [Abstract] [Full-text]
104. Effect of acidic pH on PLGA microsphere degradation and release.
     J Control Release, 122(3): 338-44. [Abstract] [Full-text]
105. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles.
     J Control Release, 122(3): 305-14. [Abstract] [Full-text]
106. PEG-based block catiomers possessing DNA anchoring and endosomal escaping functions to form polyplex micelles with improved stability and high transfection efficacy.
     J Control Release, 122(3): 252-60. [Abstract] [Full-text]
107. PEG-b-PPA/DNA micelles improve transgene expression in rat liver through intrabiliary infusion.
     J Control Release, 122(3): 297-304. [Abstract] [Full-text]
108. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).
     J Control Release, 122(3): 356-63. [Abstract] [Full-text]
109. Transdermal delivery enhanced by magainin pore-forming peptide.
     J Control Release, 122(3): 375-83. [Abstract] [Full-text]
110. Well-defined polymers with activated ester and protected aldehyde side chains for bio-functionalization.
     J Control Release, 122(3): 279-86. [Abstract] [Full-text]
111. Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life.
     J Control Release, 122(3): 209-16. [Abstract] [Full-text]
112. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems.
     J Control Release, 122(3): 287-96. [Abstract] [Full-text]
113. Reducible poly(2-dimethylaminoethyl methacrylate): synthesis, cytotoxicity, and gene delivery activity.
     J Control Release, 122(3): 217-25. [Abstract] [Full-text]
114. Paclitaxel distribution in poly(ethylene glycol)/poly(lactide-co-glycolic acid) blends and its release visualized by coherent anti-Stokes Raman scattering microscopy.
     J Control Release, 122(3): 261-8. [Abstract] [Full-text]
115. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
     J Control Release, 122(3): 365-74. [Abstract] [Full-text]
116. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer.
     J Control Release, 122(3): 226-35. [Abstract] [Full-text]
117. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses.
     J Control Release, 122(3): 345-8. [Abstract] [Full-text]
118. Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.
     Eur J Surg Oncol, 33(8): 972-6. [Abstract] [Full-text]
119. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
     Eur J Surg Oncol, 33(8): 961-6. [Abstract] [Full-text]
120. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.
     Onkologie, 30(10): 509-12. [Abstract] [Full-text]
121. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
     Nat Rev Cancer, 7(10): 750-62. [Abstract] [Full-text]
122. The impact of safety organizing, trusted leadership, and care pathways on reported medication errors in hospital nursing units.
     Med Care, 45(10): 997-1002. [Abstract] [Full-text]
123. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
     Int J Radiat Oncol Biol Phys, 69(3): 770-6. [Abstract] [Full-text]
124. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
     Cancer Lett, 256(2): 166-77. [Abstract] [Full-text]
125. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
     Int J Radiat Oncol Biol Phys, 69(3): 786-92. [Abstract] [Full-text]
126. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial.
     Neurology, 69(13): 1322-30. [Abstract] [Full-text]
127. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients.
     Stroke, 38(10): 2738-44. [Abstract] [Full-text]
128. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
     Cancer, 110(7): 1611-20. [Abstract] [Full-text]
129. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients.
     Stroke, 38(10): 2640-5. [Abstract] [Full-text]
130. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
     Stroke, 38(10): 2633-9. [Abstract] [Full-text]
131. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks.
     Cancer, 110(7): 1629-40. [Abstract] [Full-text]
132. A gap analysis approach to assess patient persistence with glaucoma medication.
     Am J Ophthalmol, 144(4): 520-4. [Abstract] [Full-text]
133. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
     Am J Ophthalmol, 144(4): 533-40. [Abstract] [Full-text]
134. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome.
     Ann Surg, 246(4): 624-8; discussion 628-31. [Abstract] [Full-text]
135. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996.
     Am J Public Health, 97(10): 1884-92. [Abstract] [Full-text]
136. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.
     Proc Natl Acad Sci U S A, 104(39): 15549-54. [Abstract] [Full-text]
137. Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline?
     Arch Dis Child, 92(10): 847-9. [Abstract] [Full-text]
138. Treatment of fever and over-the-counter medicines.
     Arch Dis Child, 92(10): 900-1. [Abstract] [Full-text]
139. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times.
     J Aerosol Med, 20(3): 320-30. [Abstract] [Full-text]
140. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology.
     J Aerosol Med, 20(3): 294-309. [Abstract] [Full-text]
141. Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV--the oropharyngeal retention effect for four inhalation delivery systems.
     J Aerosol Med, 20(3): 269-81. [Abstract] [Full-text]
142. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
     J Aerosol Med, 20(3): 227-35. [Abstract] [Full-text]
143. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer.
     Pharmacogenomics J, 7(5): 362-5. [Abstract] [Full-text]
144. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes.
     Biochem Biophys Res Commun, 363(1): 235-40. [Abstract] [Full-text]
145. Photodynamic therapy induces caspase-dependent apoptosis in rat CNV model.
     Invest Ophthalmol Vis Sci, 48(10): 4741-7. [Abstract] [Full-text]
146. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery.
     Pharm Res, 24(11): 2110-9. [Abstract] [Full-text]
147. Micelles of different morphologies--advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery.
     Pharm Res, 24(11): 2099-109. [Abstract] [Full-text]
148. Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization.
     Pharm Res, 24(11): 2040-7. [Abstract] [Full-text]
149. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives.
     Pharm Res, 24(11): 1977-92. [Abstract] [Full-text]
150. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
     Am J Kidney Dis, 50(4): 602-11. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.